HER2-Mutant NSCLC Virtual Tumor Board: Applying Advances and Best Practices in the Community Setting

Lung cancer remains the leading cause of cancer-related death, and precision medicine has made biomarker testing essential in non–small cell lung cancer (NSCLC). HER2 mutations represent an important therapeutic target, yet real-world barriers—such as access, cost, and testing delays—often limit…

Price

Free

Accredited provider:

i3 Health Joint Providership

Learning platform:

IQ Apparatus

Release date

December 18, 2025

Expires

December 17, 2026